Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Research by scientists in China has revealed two different types of coronavirus, indicating that the virus mutated at least once.

Scientists at Peking University’s School of Life Sciences and the Institut Pasteur of Shanghai designated the strains L and S.

The L type was found to be more prevalent and accounted for nearly 70%, compared to the S type at approximately 30%.

Also, the L type was prevalent in the early stages of the outbreak in Wuhan but decreased from early January. Meanwhile, the S type is said to be evolutionarily older and less aggressive.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to researchers, results indicate that development of variations in the spike present in the novel coronavirus was possibly caused by mutations, natural selection and recombination.

In a statement, the scientists said: “These findings strongly support an urgent need for further immediate, comprehensive studies that combine genomic data, epidemiological data, and chart records of the clinical symptoms of patients with coronavirus disease 2019 (Covid-19).”

However, the team analysed a limited set of data, and follow-up studies are required to understand virus evolution and epidemiology.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact